The results showed that all gene-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles appeared to have significant cytotoxicity than other control nanoparticles (P < 0.05). Especially, TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group Saracatinib HNP) had much more cytotoxicity (P < 0.01). The higher cytotoxicity of TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group HNP) may be attributed to synergistic antitumor effects of TRAIL and endostatin and the degradation

and release of TPGS from TPGS-b-(PCL-ran-PGA). It was reported that the superior antitumor activity of TPGS was due to its increasing ability to induce apoptosis [52–54]. Synergistic antitumor activities could be obtained by the use of find more combinations of TPGS and other anticancer drugs [53]. Figure

7 Viability of HeLa cells cultured with various nanoparticles in comparison with that of PBS. After 24- and 48-h incubation. (n = 5). In vivo studies The antitumor efficacy of all gene nanoparticles (groups FNP, GNP, and HNP) was further evaluated on SCID mice of an average body weight of approximately 17.8 g and an average initial tumor volume of approximately 103 mm3. The data showed that the mean survival time of mice treated with TRAIL/endostatin-loaded Q-VD-Oph solubility dmso nanoparticles was significantly longer than that of the control mice, whereas body weight among these groups had no statistical difference (P > 0.05). The average tumor growth volume was shown

in Figure 7 in comparison with those of the PBS control, blank TPGS-b-(PCL-ran-PGA) nanoparticles (group DNP), and blank TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group ENP). It can be seen from Figure 8 that TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group HNP) significantly slowed down the tumor growth of mice in comparison with the PBS control and other Adenosine triphosphate nanoparticles. Compared with the PBS control, blank TPGS-b-(PCL-ran-PGA) nanoparticles (group DNP) could also have slight anticancer efficacy. This phenomenon may be due to the degradation and release of TPGS from the TPGS-b-(PCL-ran-PGA) copolymer. It was reported that TPGS could also have superior anticancer efficacy by inducing apoptosis [52–54]. By considering the overall slope of all the curves in Figure 8, it can be concluded that the TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group HNP) have significant advantages than controls and single gene-loaded nanoparticles (groups FNP and GNP) in suppressing tumors. Thus, we could conclude that synergistic antitumor activities could be obtained by the use of combinations of TRAIL, endostatin, and TPGS. As shown in Figure 9, the images of H&E staining also indicated that tumor growth treated by TRAIL- and endostatin-loaded TPGS-b-(PCL-ran-PGA)/PEI nanoparticles (group HNP) was significantly inhibited in comparison with that of the PBS control.